58 related articles for article (PubMed ID: 7908242)
1. A structural and kinetic comparison of proto-oncogenic and oncogenic neu holo-receptors expressed in insect cells.
LeVea CM; Myers JN; Dougall WC; Qian X; Greene MI
Receptor; 1993; 3(4):293-309. PubMed ID: 7908242
[TBL] [Abstract][Full Text] [Related]
2. Neu and its ligands: from an oncogene to neural factors.
Peles E; Yarden Y
Bioessays; 1993 Dec; 15(12):815-24. PubMed ID: 7908191
[TBL] [Abstract][Full Text] [Related]
3. Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1.
Bosch E; Cherwinski H; Peterson D; McMahon M
Oncogene; 1997 Aug; 15(9):1021-33. PubMed ID: 9285556
[TBL] [Abstract][Full Text] [Related]
4. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies.
Dougall WC; Qian X; Peterson NC; Miller MJ; Samanta A; Greene MI
Oncogene; 1994 Aug; 9(8):2109-23. PubMed ID: 7913542
[TBL] [Abstract][Full Text] [Related]
5. The role of the neu oncogene product in cell transformation and normal development.
Kokai Y; Wada T; Myers JN; Brown VI; Dobashi K; Cohen J; Hamuro J; Weiner DB; Greene MI
Princess Takamatsu Symp; 1988; 19():45-57. PubMed ID: 2908355
[TBL] [Abstract][Full Text] [Related]
6. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.
Weiner DB; Liu J; Cohen JA; Williams WV; Greene MI
Nature; 1989 May; 339(6221):230-1. PubMed ID: 2654648
[TBL] [Abstract][Full Text] [Related]
7. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
[TBL] [Abstract][Full Text] [Related]
8. Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation.
Qian X; Dougall WC; Hellman ME; Greene MI
Oncogene; 1994 May; 9(5):1507-14. PubMed ID: 7908733
[TBL] [Abstract][Full Text] [Related]
9. Bivalence of EGF-like ligands drives the ErbB signaling network.
Tzahar E; Pinkas-Kramarski R; Moyer JD; Klapper LN; Alroy I; Levkowitz G; Shelly M; Henis S; Eisenstein M; Ratzkin BJ; Sela M; Andrews GC; Yarden Y
EMBO J; 1997 Aug; 16(16):4938-50. PubMed ID: 9305636
[TBL] [Abstract][Full Text] [Related]
10. ErbB kinases and NDF signaling in human prostate cancer cells.
Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
[TBL] [Abstract][Full Text] [Related]
11. Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases.
Guy PM; Carraway KL; Cerione RA
J Biol Chem; 1992 Jul; 267(20):13851-6. PubMed ID: 1352772
[TBL] [Abstract][Full Text] [Related]
12. Polymorphic changes of cell phenotype caused by elevated expression of an exogenous NEU proto-oncogene.
Tarakhovsky AM; Resnikov M; Zaichuk T; Tugusheva MV; Butenko ZA; Prassolov VS
Oncogene; 1990 Mar; 5(3):405-10. PubMed ID: 1969137
[TBL] [Abstract][Full Text] [Related]
13. Demonstration by two-color flow cytometry that tyrosine kinase activity is required for down-modulation of the oncogenic neu receptor.
Brown VI; Shah N; Smith R; Hellman M; Jarett L; Mikami Y; Cohen E; Qian X; Greene MI
DNA Cell Biol; 1994 Feb; 13(2):193-209. PubMed ID: 7910024
[TBL] [Abstract][Full Text] [Related]
14. Ligand-independent oncogenic transformation by the EGF receptor requires kinase domain catalytic activity.
Danielsen AJ; Maihle NJ
Exp Cell Res; 2002 Apr; 275(1):9-16. PubMed ID: 11925101
[TBL] [Abstract][Full Text] [Related]
15. Expression, purification, and characterization of Bacneu. A soluble protein tyrosine kinase domain encoded by the neu-oncogene.
Myers JN; LeVea CM; Smith JE; Kallen RG; Tung L; Greene MI
Receptor; 1992; 2(1):1-16. PubMed ID: 1362129
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic activation of the tyrosine kinase domain of the human trk proto-oncogene by fusion to a cell adhesion molecule.
Albor A; Thraves PJ; Dritschilo A; Notario V
Oncogene; 1996 Oct; 13(8):1755-63. PubMed ID: 8895522
[TBL] [Abstract][Full Text] [Related]
17. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.
Pinkas-Kramarski R; Soussan L; Waterman H; Levkowitz G; Alroy I; Klapper L; Lavi S; Seger R; Ratzkin BJ; Sela M; Yarden Y
EMBO J; 1996 May; 15(10):2452-67. PubMed ID: 8665853
[TBL] [Abstract][Full Text] [Related]
18. The effects of the normal and oncogenic forms of the neu tyrosine kinase, and the corresponding forms of an immunoglobulin E receptor/neu tyrosine kinase fusion protein, on Xenopus oocyte maturation.
Narasimhan V; Hamill O; Cerione RA
FEBS Lett; 1992 Jun; 303(2-3):164-8. PubMed ID: 1351469
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene.
Zhai YF; Beittenmiller H; Wang B; Gould MN; Oakley C; Esselman WJ; Welsch CW
Cancer Res; 1993 May; 53(10 Suppl):2272-8. PubMed ID: 8097963
[TBL] [Abstract][Full Text] [Related]
20. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.
Altenschmidt U; Kahl R; Moritz D; Schnierle BS; Gerstmayer B; Wels W; Groner B
Clin Cancer Res; 1996 Jun; 2(6):1001-8. PubMed ID: 9816261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]